Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide compared to placebo in people with opioid use disorder OUD who are also receiving buprenorphine treatment, with or without naloxone. This Phase 2 study includes participants with mild to severe OUD and aims to assess abstinence from opioid use over a defined period. The study has two parts Part A involves a double-blind treatment phase followed by an open-label extension, while Part B includes only open-label treatment. Participants receive brenipatide or placebo by subcutaneous injection alongside buprenorphine administered under the tongue or in the cheek. Each participant enrolls in only one part, with treatment durations up to approximately 144 weeks in Part A and 116 weeks in Part B. Participants attend regular study visits for assessments, including urine drug screens and self-reports to measure opioid abstinence, adherence to buprenorphine, and changes in craving and quality of life. Other evaluations include monitoring for overdose events, healthcare utilization, body measurements, and blood pressure. Safety is tracked through laboratory tests and antibody monitoring, with the overall study lasting up to several years depending on enrollment timing.
Actively Recruiting
Researchers are evaluating the antidepressant effects of ALTO-100 compared to a placebo in adults with Bipolar Disorder I or II who are currently experiencing a major depressive episode. This study aims to understand how patient characteristics may influence treatment outcomes when ALTO-100 is used along with a mood stabilizer andor an atypical antipsychotic. The trial also focuses on assessing safety, tolerability, and efficacy during a later open-label treatment phase. Participants in the study will be randomly assigned to receive either ALTO-100 at a dose of 40 mg twice daily or a matching placebo for 6 weeks during the double-blind treatment period. Those who qualify and continue will enter an open-label period lasting up to 7 weeks, where all will receive ALTO-100 40 mg twice daily. The study uses a quadruple-blind design to ensure unbiased results. During the trial, participants will undergo regular assessments of depression symptoms using scales such as the Montgomery-sberg Depression Rating Scale MADRS, Patient Health Questionnaire PHQ-9, and Clinician Global Impression Scale-severity CGI-S. Safety monitoring includes tracking adverse events, heart rate, blood pressure, weight, and suicidality over a total period of up to 13 weeks. The study evaluates changes from baseline to week 6 during the double-blind phase and continues safety assessments through the open-label period.
Actively Recruiting
This study focuses on adults in the United States with schizophrenia who are prescribed xanomeline and trospium chloride XT therapy. It aims to understand patients treatment preferences and satisfaction with this medication combination. The research is observational and tracks real-world experiences rather than testing new treatments. Participants receive xanomeline and trospium chloride therapy according to the product label. The study observes how patients use this treatment and collects information about dosing and any changes over time. Data is gathered at multiple points, including baseline, Month 1, Month 3, and Month 6, to monitor treatment plans and medication adjustments. During the study, participants provide information through questionnaires about their medication preferences and satisfaction. Researchers also collect clinical and demographic data, track treatment plans, dose changes, and reasons for discontinuing therapy. This information helps assess the real-world use and patient experience with XT therapy over approximately six months.
Actively Recruiting
Researchers are evaluating the efficacy of ALTO-300 compared to placebo as an add-on treatment to antidepressants in adults with moderate to severe major depressive disorder MDD. This Phase 2 study aims to understand how patient characteristics might influence the effectiveness of ALTO-300 in improving depression symptoms. The study uses a randomized, double-blind, placebo-controlled design with a subsequent open-label extension phase. Participants will be assigned to receive either ALTO-300 capsules or matching placebo capsules once daily in the evening for 42 days during the double-blind period. Those who qualify for the open-label phase will continue taking ALTO-300 daily for up to an additional 8 weeks. Throughout both phases, the study monitors treatment effects and safety. During the trial, participants will undergo assessments to measure changes in depression symptoms using the Montgomery-sberg Depression Rating Scale MADRS over six weeks. Safety evaluations include monitoring adverse events, heart rate, weight, blood pressure, and suicidality through specialized questionnaires. The total study duration includes the double-blind phase and the open-label extension, with ongoing safety and efficacy monitoring until study completion.